Skin Cancer pp 378-389 | Cite as

Topical Chemotherapy

  • Krzysztof Dabski
  • Frederick Helm


Physical or chemical cautery were the only treatments available for skin cancer for centuries. Arsenicals were used for topical cautery in the 18th century. After World War I, topical sulfur mustard was found to be effective in slowing cancer growth. Podophyllin varying in strength from 15% to 25% was used to treat skin cancers as well. One percent colchicine in vaseline was used as topical treatment by Hirsch in 1951 (1), but the realization that topical therapy could halt skin cancer had the greatest impact of all. Man intensified his search for chemicals that could help him fight disease.


Basal Cell Carcinoma Allergic Contact Dermatitis Actinic Keratose Mycosis Fungoides Bullous Pemphigoid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hirsch H: Effect of colchicine increased by simultaneous administration of bulbocapnine in the treatment of skin cancer. Dermatol Wschr 1951; 123:389–390.Google Scholar
  2. 1a.
    Rutman RJ, Cantrow A, Paschkis KE: Studies on 2-acetyl-aminofluorenecarcinogenesis: Utilization of uracil-2-C14 by preneoplastic rat liver hepatoma. Cancer Res 1954; 14:119–123.PubMedGoogle Scholar
  3. 2.
    Cohen SS, Barner HD: Studies on the induction of thymine deficiency on the effects of thymine and thymidine analogs in Escherichia coli. J Bacteriol 1957; 71:588–597.Google Scholar
  4. 3.
    Heidelberger C, Chaudhuri NK, Danneburg P, et al: Fluorinated pyrimidines: A new class of tumor-inhibitory compounds. Nature 1957; 179: 663–666.PubMedGoogle Scholar
  5. 4.
    Curreri AR, Ausfield FJ, Mclver FA, et al: Clinical studies with 5-fluorouracil. Cancer Res 1958; 18:478–484.PubMedGoogle Scholar
  6. 5.
    Heidelberger C, Ansfield FJ: Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res 1963; 23:1226–1243.PubMedGoogle Scholar
  7. 6.
    Falkson G, Schulz EJ: Skin changes in patients treated with 5-fluorouracil. Br J Dermatol 1962; 74:229–236.PubMedGoogle Scholar
  8. 7.
    Belisario JC: Ten years’ experience with topical cytotoxic therapy for cutaneous cancer and precancer-type and number of lesions treated (Part I). Cutis 1970; 6:293–306.Google Scholar
  9. 8.
    Belisario JC: Topical cytotoxic therapy for cutaneous cancer and precancer, in Epstein E (Ed): Springfield, IL, Skin Surgery (4th ed). Charles C Thomas, 1977, pp 472–500.Google Scholar
  10. 9.
    Belisario JC: Recent advances in topical cytotoxic therapy of skin cancer and precancer, in Melanoma and Skin Cancer. New South Wales, Australia, V.C.N. Blight, Government printer, 1972, p 349.Google Scholar
  11. 10.
    Klein E, Stoll HL Jr, Milgrom H, et al: Tumors of the skin: V. Local administration of anti-tumor agents to multiple superficial basal cell carcinomas. J Invest Dermatol 1965; 45:489–497.PubMedGoogle Scholar
  12. 11.
    Klein E, Milgrom H, Helm F: Tumors of the skin: Effects of local use of cytostatic agents. Skin 1962; 1:81–87.PubMedGoogle Scholar
  13. 12.
    Klein E, Helm F, Milgrom H: Tumors of the skin: II. Keratoacanthoma: Local effect of 5-fluorouracil. Skin 1962; 1:153–156.PubMedGoogle Scholar
  14. 13.
    Miller E: The metabolism and pharmacology of 5-fluorouracil. J Surg Oncol 1971; 3:309–315.PubMedGoogle Scholar
  15. 14.
    Heidelberger C, Ghobar A, Baker RK, et al: Studies of fluorinated pyrimidines: X. In vivo studies on tumor resistance. Cancer Res 1960; 20:897–902.PubMedGoogle Scholar
  16. 15.
    Bollag W: The place of 5-fluorouracil in experimental and clinical cancer chemotherapy. Dermatologica 1970; 140 (Suppl 1):1–6.PubMedGoogle Scholar
  17. 16.
    Greenwald E (Ed): Cancer Chemotherapy (2nd ed). Medical Outline Series, Medical Examination Publishing Co., 1973, Flushing, New York pp 205–208.Google Scholar
  18. 17.
    Dillaha CJ, Jansen T, Honeycutt MW, et al: Further studies with topical 5-fluorouracil. Arch Dermatol 1965; 92:410–417.PubMedGoogle Scholar
  19. 18.
    Cohen JL, Stoughton RB: Penetration of 5-fluorouracil in excised skin. J Invest Dermatol 1974; 62:507–509.PubMedGoogle Scholar
  20. 19.
    Murkheŗjee KL, Curreri AR, Javid M, et al: Studies on fluorinated pyrimidines: XVII. Tissue distribution of 5-fluorouracil-2 C14 and 5-fluoro2-deoxyuridine in cancer patients. Cancer Res 1963; 23:67–77.Google Scholar
  21. 20.
    Dillaha CJ, Janset GT, Honeycutt WM, et al: Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol 1963; 88:247–256.PubMedGoogle Scholar
  22. 21.
    Eaglstein WH, Weinstein GD, Frost P: Fluorouracil: Mechanism of action in human skin and actinic keratoses. Arch Dermatol 1970; 101:132–139.PubMedGoogle Scholar
  23. 22.
    Salem PA, Sykes M: The effect of topical 5-fluorouracil on normal skin. Proceedings of Tenth International Cancer Congress, 1970, Chicago, Year Book 1971, p 494.Google Scholar
  24. 23.
    Neldner KH: Prevention of skin cancer with topical 5-fluorouracil. Rocky Mt Med J 1966; 63:74–78.PubMedGoogle Scholar
  25. 24.
    Williams AC, Klein E: Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions. Cancer 1970; 25:450–462.PubMedGoogle Scholar
  26. 25.
    DeMoragas JM, Gimenez-Camarasa JM: 5-Fluorouracil ointment in tumors of the skin. Dermatologica 1970; 140(Suppl 1):65–74.Google Scholar
  27. 26.
    Carter VH, Smith KW, Noojin RO: Xeroderma pigmentosum: Treatment with topically applied 5-fluorouracil. Arch Dermatol 1968; 98:526–527.PubMedGoogle Scholar
  28. 27.
    Lynch JL: Xeroderma pigmentosum. Arch Dermatol 1968; 101:495–496.Google Scholar
  29. 28.
    Klein E, Stoll HL, Milgrom H, et al: Tumors of the skin: IV. Double blind study on effect of local administration of antitumor agents in basal cell carcinomas. J Invest Dermatol 1965; 44:351–353.PubMedGoogle Scholar
  30. 29.
    Klein E, Stoll HL, Milgrom H, et al: Tumors of the skin: VI. Study on effects of local administration of 5-fluorouracil in basal cell carcinomas. J Invest Dermatol 1966; 47:22–26.Google Scholar
  31. 30.
    Stoll HL, Klein E, Case RW: Tumors of the skin: VII. Effects of varying the concentration of locally administered 5-fluorouracil on basal cell carcinomas. J Invest Dermatol 1967; 49:219–224.Google Scholar
  32. 31.
    Moynahan EJ: Multiple basal cell nevus syndrome: Successful treatment of basal cell tumours with 5-fluorouracil. Proc R Soc Med 1973; 66:627–628.PubMedGoogle Scholar
  33. 32.
    Amon RB, Goodkin PE: Topical 5-fluorouracil and the basal cell nevus syndrome. N Engl J Med 1976; 295:677–678.PubMedGoogle Scholar
  34. 33.
    Haynes HA: Topical 5-fluorouracil and the basal cell nevus syndrome. N Engl J Med 1976; 295:678.Google Scholar
  35. 34.
    Wiskemann A: Pharmakologischer Lichtschutz durch Bausteine der Nukleinsäuren im Tierversuch. Strahlentherapie 1971; 141:752–755.PubMedGoogle Scholar
  36. 35.
    Jansen GT: Topical therapy with 5-fluorouracil. J Surg Oncol 1971; 3:317–323.PubMedGoogle Scholar
  37. 36.
    Kestel J Jr: Treatment of actinic keratoses. Arch Dermatol 1970; 102:351.PubMedGoogle Scholar
  38. 37.
    Almeida Goncalves JC: Treatment of actinic keratoses with 5-fluorouracil and salicylic acid varnish. Br J Dermatol 1975; 92:85–88.Google Scholar
  39. 38.
    Bercovitch L: Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: A double-blind controlled study. Br J Dermatol 1987; 116:549–552.PubMedGoogle Scholar
  40. 39.
    Stoll HL Jr: Chemotherapy, in Helm F (Ed): Cancer Dermatology Philadelphia, Lea & Febiger, 1979, pp 435–447.Google Scholar
  41. 40.
    Rossman RE: Topical fluorouracil therapy. South Med J 1969; 62:1240–1242.PubMedGoogle Scholar
  42. 41.
    Simmonds WL: Management of actinic keratoses with topical 5-fluorouracil. Cutis 1976; 18:298–230.PubMedGoogle Scholar
  43. 42.
    Goette DK: Topical chemotherapy with 5-fluorouracil: A review. J Am Acad Dermatol 1981; 4:633–648.PubMedGoogle Scholar
  44. 43.
    Klein E: Hypersensitivity reactions at tumor sites. Cancer Res 1969; 29:2351–2362.PubMedGoogle Scholar
  45. 44.
    Helm F, Klein E: Effects of allergic contact dermatitis on basal cell epitheliomas. Arch Dermatol 1965; 91:142–144.PubMedGoogle Scholar
  46. 45.
    Goette DK, Odom RB: Allergic contact dermatitis to topical fluorouracil. Arch Dermatol 1977; 113:1058–1061.PubMedGoogle Scholar
  47. 46.
    Almeida Goncalves JC: Fluorouracil ointment treatment of porokeratosis of Mibelli. Arch Dermatol 1973; 108:131–132.Google Scholar
  48. 47.
    Schreiber MM: Systemic fluorouracil photosensitivity. Cutis 1978; 22:609–610.PubMedGoogle Scholar
  49. 48.
    Horio T, Murai T, Ikai K: Photosensitivity due to a fluorouracil derivative. Arch Dermatol 1978; 114:1498–1500.PubMedGoogle Scholar
  50. 49.
    Hrushesky WJ: Serpentine supravenous 5-fluorouracil (NSC-19893) hyperpigmentation. Cancer Treat Rep 1976; 60:639.PubMedGoogle Scholar
  51. 50.
    Sykes MP: The effect of topical 5-fluorouracil on normal skin (Abstract of a paper). Proceedings of the International Cancer Congress, May 1970, Houston, TX, p 493.Google Scholar
  52. 51.
    Ippen H: The photoprotective effect and pharmaceutical properties of 5-fluorouracil ointment. Dermatologica 1970; 140(Suppl 1): 15–20.PubMedGoogle Scholar
  53. 52.
    Sams WM: Untoward response with topical 5-fluorouracil. Arch Dermatol 1968; 97:14–22.PubMedGoogle Scholar
  54. 53.
    Jansen GT, Dillaha CJ, Honeycutt WM: Bowenoid conditions of the skin: Treatment with topical 5-fluorouracil. South Med J 1967; 60:185–188.PubMedGoogle Scholar
  55. 54.
    Kaplan LA, Walter JF, Macknet KD: Hypertrophic scarring as a compilation of fluorouracil therapy. Arch Dermatol 1979; 115:1452.PubMedGoogle Scholar
  56. 55.
    Baran R, Laugier P: Melanonychia induced by topical 5-fluorouracil. Br J Dermatol 1985; 112:621–625.PubMedGoogle Scholar
  57. 56.
    Bart BJ, Bean SF: Bullous pemphigoid following the topical use of fluorouracil. Arch Dermatol 1970; 102:457–460.PubMedGoogle Scholar
  58. 57.
    Burgess GH, Bloch A, Stoll HL, et al: Effect of topical tubercidin on basal cell carcinomas and actinic keratoses. Cancer 1974; 34:250–253.PubMedGoogle Scholar
  59. 58.
    Calabresi P, Parks RE Jr: Chemotherapy of neoplastic diseases, in Goodman LS, Gilman A (Eds): The Pharmacological Basis of Therapeutics (5th ed). New York, Macmillan, 1975, pp 1250–1252.Google Scholar
  60. 59.
    Gilman A, Philips FS: The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science 1946; 103:409–415.Google Scholar
  61. 60.
    Sipos K, Jasko G: A mustarnirogen helyi alkamazasa nehany borbetegsegben. Borgyogyaszati es Venerologiai Szemle 1956; 32:198–203.Google Scholar
  62. 61.
    Arundell FD: Mycosis fungoides: Topical use of nitrogen mustard in recurrent cases. Calif Med 1968; 109:458–461.PubMedGoogle Scholar
  63. 62.
    Haserick JR, Richardson JH, Grant D: Remission of lesions in mycosis fungoides following topical application of nitrogen mustard. Cleve Clin Q 1959; 26:144–147.Google Scholar
  64. 63.
    Wong E, Holden CA, Broadbent V, Atherton DJ: Histiocytosis X presenting as intertrigo and responding to topical nitrogen mustard. Clin Exp Dermatol 1986; 11:183–187.PubMedGoogle Scholar
  65. 64.
    Klein E, Schwartz RA, Case SW, et al: Accessible tumors, in LoBuglio AF (Ed): Clinical Immunotherapy. New York, Marcel Dekker, 1980, p 48.Google Scholar
  66. 65.
    Constantine VS, Fuks ZY, Farber EM: Mechlorethamine desensitization in therapy for mycosis fungoides. Arch Dermatol 1975; 111:484–488.PubMedGoogle Scholar
  67. 66.
    Price NM, Hoppe RT, Constantine VS, et al.: Topical mechlorethamine therapy for mycosis fungoides. Br J Dermatol 1977; 97:547–555.PubMedGoogle Scholar
  68. 67.
    Price NM, Hoppe RT, Constantine VS, et al: The treatment of mycosis fungoides: Adjuvant topical mechlorethamine after electron beam therapy. Cancer 1977; 40:2851–2853.PubMedGoogle Scholar
  69. 68.
    Inch WR, McCredic JA: Effect of aging aqueous nitrogen mustard on white blood cell count, body weight and Walker 256 tumor in the rat. Can J Biochem 1963; 41:417–425.PubMedGoogle Scholar
  70. 69.
    Van Scott EJ, Yu RJ: Antimitotic, antigenic and structural relationships of nitrogen mustard and its homologues. J Invest Dermatol 1974; 62:378–383.PubMedGoogle Scholar
  71. 70.
    Porres JM: Reduced Sensitization to Mechlorethamine in a Nonpolar Vehicle: The Therapeutic Value in Psoriasis. Paper presented at the 36th Annual Meeting of the American Academy of Dermatology, Dallas, Dec 5, 1977.Google Scholar
  72. 71.
    Streilein JW, Toews GB, Bergstresser PR: Langerhans cells: Functional aspects revealed by in vivo grafting studies. J Invest Dermatol 1980; 75:17–21.PubMedGoogle Scholar
  73. 72.
    Streilein JW, Toews GB, Gilliam JN, et al: Tolerance of hypersensitivity to 2,4-dinitro-1-fluorobenzene: The role of Langerhans cells density within the epidermis. J Invest Dermatol 1980; 74:319–322.PubMedGoogle Scholar
  74. 73.
    Bergstresser PR, Toews GB, Gilliam JN, et al: Unusual numbers and distribution of Langerhans cells in skin with unique immunologic properties. J Invest Dermatol 1980; 74:312–314.PubMedGoogle Scholar
  75. 74.
    Bergstresser PR, Toews GB, Streilein JW: Natural and perturbed distributions of Langerhans cells: Response to ultraviolet light, heterotopic skin grafting and dinitrofluorobenzene sensitization. J Invest Dermatol 1980; 75:73–77.PubMedGoogle Scholar
  76. 75.
    Toews GB, Bergstresser PR, Streilein JW: Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 1980; 124:445–453.PubMedGoogle Scholar
  77. 76.
    Morison WL, Parrish JA: Further studies of the effect of PUVA and UV-B radiation on delayed hypersensitivity of guinea pig. J Invest Dermatol 1980; 74:259 (Abstr).Google Scholar
  78. 77.
    Noonan F, Pederson G, Kripke M: Ultraviolet radiation suppresses cell-mediated immunity. J Invest Dermatol 1980; 74:261 (Abstr).Google Scholar
  79. 78.
    O’Dell BL, Jessen RT, Becker IE, et al: Diminished immune response in sun damaged skin. Arch Dermatol 1980; 116:559–561.PubMedGoogle Scholar
  80. 79.
    Halprin KM, Comerford M, Presser SE, et al: Ultraviolet light treatment delays contact sensitization to nitrogen mustard. Br J Dermatol 1981; 105:71–76.PubMedGoogle Scholar
  81. 80.
    Vega FA, Halprin KM, Taylor JR, et al: Failure of periodic ultraviolet radiation treatments to prevent sensitization to nitrogen mustard: A case report. Br J Dermatol 1982; 106:361–366.PubMedGoogle Scholar
  82. 81.
    Van Scott FJ, Kalmanson JD: Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN-2): Control of delayed hypersensitivity of HN-2 by desensitization and induction of specific immunologic tolerance. Cancer 1970; 32:18–30.Google Scholar
  83. 82.
    Ragner AC, Waldorf DS, Van Scott EJ: Alterations of lesions of mycosis fungoides lymphoma by direct imposition of delayed hypersensitivity reactions. Cancer 1968; 21:83–88.Google Scholar
  84. 83.
    Shelley WB: Focal contact sensitivity to nitrogen mustard in lesions of cutaneous T-cell lymphoma (mycosis fungoides). Acta Derm Venereol (Stockh) 1981; 61:161–164.PubMedGoogle Scholar
  85. 84.
    Du Vivier A, Vonderheid EC, Van Scott EJ, et al: Mycosis fungoides, nitrogen mustard and skin cancer. Br J Dermatol 1978; 99:61–63.PubMedGoogle Scholar
  86. 85.
    Kravitz PH, McDonald DJ: Topical nitrogen mustard induced carcinogenesis. Acta Derm Venereol (Stockh) 1978; 58:421–425.PubMedGoogle Scholar
  87. 86.
    Lee LA, Fritz KA, Goltz L, et al: Second cutaneous malignancies in patients with mycosis fungoides treated with topical nitrogen mustard. J Am Acad Dermatol 1982; 7:590–598.PubMedGoogle Scholar
  88. 87.
    Abel EA, Sendagorta E, Hoppe RT: Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides. J Am Acad Dermatol 1986; 14:1029–1038.PubMedGoogle Scholar
  89. 88.
    Clendenning WE: Perspectives on cutaneous T cell lymphoma. Clin Exp Dermatol 1986; 11:107–126.Google Scholar
  90. 89.
    Zackheim HS, Epstein EH Jr, McNutt NS, et al: Topical carmustine (BCNU) for mycosis fungoides and related disorders: A 10-year experience. J Am Acad Dermatol 1983; 9:363–374.PubMedGoogle Scholar
  91. 90.
    Helm F, Klein E: Effects of allergic contact dermatitis on basal cell epitheliomas. Arch Dermatol 1965; 91:142–144.PubMedGoogle Scholar
  92. 91.
    Helm F, Klein E, Rivera EP: Studies on local administration of 2, 3, 5-tri-ethylene-imino-(1, 4)-benzoquinone (trenimon). On epithiomas and keratoses. J Invest Dermatol 1965; 45:152–159.PubMedGoogle Scholar
  93. 92.
    Wolbach SB, Howe PR: Tissue changes following deprivation of fat soluble A vitamin. J Exp Med 1925; 42:753–777.PubMedGoogle Scholar
  94. 93.
    Verma AK, Shapas BG, Rice HM, et al: Correlation of the inhibition by retinoids of tumor promoter induced mouse epidermal ornithine decarboxylate activity and of skin tumor promotion. Cancer Res 1979; 39:419–425.PubMedGoogle Scholar
  95. 94.
    Stuttgen G: Zur lokalbehandlung von keratosen mit vitamin-A saure. Dermatologica 1962; 124:192–195.Google Scholar
  96. 95.
    Bercovitch L: Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fIuorouraciI: A double-blind controlled study. Br J Dermatol 1987; 116:549–552.PubMedGoogle Scholar
  97. 96.
    Peck GL: Topical tretinoin in actinic keratosis and basal cell carcinoma. J Am Acad Dermatol 1986; 15:829–835.PubMedGoogle Scholar
  98. 97.
    Meyskens FL Jr, Edwards L, Levine NS: Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol 1986; 15:822–825.PubMedGoogle Scholar
  99. 98.
    Kessler JF, Jones SE, Levine N, et al: Isotretinin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987; 123:201–204.PubMedGoogle Scholar
  100. 99.
    Kligman AM, Grove GL, Hirose R, Leyden JJ: Topical tretinoin for photoaged skin. J Am Acad Dermatol 1986; 15:836–859.PubMedGoogle Scholar
  101. 100.
    Lippman SM, Kessler JF, Meyskens FL Jr: Retinoids as preventive and therapeutic anticancer agents (Part 1). Cancer Treat Rep 1987; 71:391–405.PubMedGoogle Scholar
  102. 101.
    Lippman SM, Meyskens FL Jr: Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 1987; 107:499–501.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1988

Authors and Affiliations

  • Krzysztof Dabski
  • Frederick Helm

There are no affiliations available

Personalised recommendations